Medexus to Present at the Sidoti & Company Virtual Microcap Conference on May 19th

May 12, 2021 8:30 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

TORONTO, CHICAGO and MONTREAL, May 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Sidoti & Company Virtual Microcap Conference being held on May 19th - May 20th, 2021.

Ken d’Entremont, Chief Executive Officer, and Roland Boivin, Chief Financial Officer of Medexus, are scheduled to present on Wednesday, May 19, 2021 at 9:15 AM, Eastern Time. The presentation will be webcast live and available for replay here as well as on the Company’s website at In addition to the presentation, management will also be hosting virtual one-on-one meetings throughout the day on both Wednesday, May 19th and Thursday, May 20th. Interested investors should contact the Sidoti Marketing Team at 212-453-7031 or to schedule a meeting.

About Medexus Pharmaceuticals Inc.

Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action.

For more information, please contact:

Ken d’Entremont, Chief Executive OfficerMedexus Pharmaceuticals Inc.Tel.: 905-676-0003E-mail:

Roland Boivin, Chief Financial OfficerMedexus Pharmaceuticals Inc.Tel.: 514-344-8765E-mail:

Investor Relations (U.S.):Crescendo Communications, LLCTel: +1-212-671-1020Email:

Investor Relations (Canada):Tina ByersAdelaide Capital Tel: 905-330-3275E-mail: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Primary Logo

Source: Medexus Pharmaceuticals Inc

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Globe Newswire, Press Releases

Related Entities

Sidoti & Company